Veronica Bruno

Veronica Bruno

Auto-generated profile, based on publicly available information

Veronica Bruno

Department of Clinical Neurosciences University of Calgary Calgary Alberta Canada

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2025 in Movement Disorders
Verified
Journal Article
Open access
RBRob M.A. de Bie
Rob M.A. de Bie
RKRegina Katzenschlager
Regina Katzenschlager
BSBart E.K.S. Swinnen
Bart E.K.S. Swinnen
MPMarina Peball
Marina Peball
SLShen‐Yang Lim
Shen‐Yang Lim
Monty SilverdaleMonty Silverdale
Monty Silverdale
Objective: To update evidence‐based medicine recommendations for treating motor fluctuations of Parkinson's disease (PD).Background: The International Parkinson and Movement Disorder Society (MDS) Evidence Based Medicine in Movement Disorders Committee recommendations for the treatments of PD were first published in 2002 and regularly updated. The current review uses a new methodology, including the Cochrane Risk of Bias tool and a modified version of GRADE (Grading of Recommendations, Assessment, Development, and Evaluations).Methods: On January 1, 2023, a literature search was conducted without date limit in the MEDLINE, Embase, and Cochrane databases using the following search terms: Parkinson disease, levodopa and, for the Embase database, randomized controlled trial (RCT). The inclusion criteria for studies were: patients with PD, on oral levodopa therapy, experiencing motor fluctuations, investigating an intervention that was (commercially) available in at least one country, study design RCT, and with a follow‐up duration of at least 3 months.Results: A total of 102 studies were included. Levodopa extended release, pramipexole immediate release and extended release, ropinirole immediate release, rotigotine, opicapone, safinamide, and bilateral subthalamic nucleus deep brain stimulation (DBS) were assessed as efficacious, and continuous intestinal levodopa infusion, continuous subcutaneous levodopa, continuous subcutaneous apomorphine, ropinirole prolonged release, ropinirole patch, entacapone, rasagiline, istradefylline, amantadine extended release, zonisamide, bilateral globus pallidus DBS, and pallidotomy were assessed as likely efficacious for the treatment of motor fluctuations in people with PD who are already being treated with levodopa.Conclusions: There are several treatment options that can improve motor fluctuations in PD. These recommendations will assist physicians and patients in determining which intervention to use. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

1 June 2016 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Verified
Journal Article
Closed access
PDF file
VBVeronica A. Bruno
Veronica A. Bruno
SFSusan H. Fox
Susan H. Fox
DMDeborah Mancini
Deborah Mancini
Janis M MiyasakiJanis M Miyasaki
Janis M Miyasaki
Background: Parkinson’s disease (PD) and other parkinsonian syndromes are chronic, progressive neurodegenerative diseases. With advancing disease, both motor and non-motor symptoms represent a considerable burden and symptom relief and quality of life improvement become the main goal of treatment. Botulinum toxins (BTX) are an effective treatment modality for many neurological conditions. Methods: To understand the potential usefulness of BTX in this population, we performed a retrospective chart review of all patients with a clinical diagnosis of idiopathic PD and atypical parkinsonism who received treatment with BTX injections in our center from 1995 to 2014 for a variety of symptoms. Response to BTX was assessed using a subjective Clinical Global Impression. Results: Records of 160 patients were reviewed. Probable idiopathic PD was the diagnosis in 117 patients (73.1%). The main indication for BTX treatment was pain (50.6% of cases). Other indications were the treatment of functional impairment resulting from dystonia (26.25%), sialorrhea (18.75%), freezing of gait, and camptocormia. Considering pain as indication, 81% of all patients with PD reported benefits after the first BTX injections. This benefit was maintained after the last recorded visit without significant difference in outcome compared with the first injection (p=0.067). Similar results were observed in patients with atypical parkinsonism. Conclusions: Our results confirm the safety and efficacy of different uses of BTX in the symptomatic treatment of patients with parkinsonism even in advanced stages of the disease, and suggest BTX treatment could have a safe and useful role in the treatment of pain in this population.

15 February 2016 in Current Neurology and Neuroscience Reports
Verified
Journal Article
Closed access
PDF file
CGChristian Geroin
Christian Geroin
Marialuisa GandolfiMarialuisa Gandolfi
Marialuisa Gandolfi
VBVeronica Bruno
Veronica Bruno
Nicola SmaniaNicola Smania
Nicola Smania
MTMichele Tinazzi
Michele Tinazzi

1 March 2016 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
VBVeronica Bruno
Veronica Bruno
DMDeborah Mancini
Deborah Mancini
RGRoger Ghoche
Roger Ghoche
RARena Arshinoff
Rena Arshinoff
Janis M MiyasakiJanis M Miyasaki
Janis M Miyasaki

7 November 2017 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Verified
Journal Article
Closed access
PDF file
VBVeronica Bruno
Veronica Bruno
MFMaria Eliza Freitas
Maria Eliza Freitas
DMDeborah Mancini
Deborah Mancini
JLJane P. Lui
Jane P. Lui
JMJanis Miyasaki
Janis Miyasaki
SFSusan H. Fox
Susan H. Fox
Background and ObjectivePain is a frequent symptom in Parkinson’s disease (PD), and the therapeutic alternatives are scarce. The goal of this trial was to measure the effects of botulinum toxin type A (BTXA) in the treatment of limb pain in advanced PD.MethodsA randomized double-blind crossover versus placebo study of BTXA for limb pain in advanced Parkinson’s disease was conducted. Subjects received individualized BTXA/placebo dosing per pain distribution in limbs. The primary outcome was a measure of change in global pain on a numeric rating scale (NRS) at 4 and 12 weeks postinjection and on a visual analogue scale 12 weeks after treatment. Secondary outcomes included the percentage of responders, physician-rated clinical global impressions, MDS–UPDRS and PDQ–39 scores, and adverse events.ResultsA total of 12 subjects completed the trial. Treatment with BTXA (average dose=241.66 U) produced a significant reduction in NRS score 4 weeks after the injections (–1.75 points, range from –3 to 7,p=0.033). However, there was no significant difference compared to placebo (p=0.70). Participants with dystonic pain showed a greater reduction in NRS score after 4 weeks when treated with BTXA (2.66 points vs. 0.75 for placebo). There were no significant differences for any of the secondary outcomes or significant adverse events.ConclusionsTargeted BTXA injections were safe in patients with limb pain and advanced PD; however, the present study failed to show a significant effect when compared to placebo. Further studies may be focused on evaluating the effect of BTXA particularly in dystonic pain.

13 January 2020 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Verified
Journal Article
Closed access
PDF file
VKVikram Karnik
Vikram Karnik
NFNicole Farcy
Nicole Farcy
CZCarolina Zamorano
Carolina Zamorano
VBVeronica Bruno
Veronica Bruno
Background: Pain is a non-motor symptom in Parkinson’s disease (PD) which commonly goes underreported. Adequate treatment for pain in PD remains challenging, and to date, no clear guidelines for management are available.Methods: With the goal of understanding and organizing the current status of pain management in PD, we conducted a review of pharmacological and non-pharmacological treatments for pain in patients with PD. Suitable studies cataloged in PubMed and the Cochrane database up to October 31, 2019, were included prioritizing randomized controlled trials.Post-hocanalyses and open-label studies were also included.Results: Treatment with levodopa increases pain thresholds in patients with PD. Apomorphine did not have similar efficacy. Duloxetine provided benefit in an open-label trial. Oxycodone-naloxone PR did not have a significant improvement in pain, but per-protocol analysis showed a reduction in pain when adherence was strong. Rotigotine patch had numerical improvement on pain scales with no statistical significance. Safinamide significantly improved the “bodily discomfort” domain in the PDQ-39 questionnaire. Botulinum toxin A had a non-significant signal toward improving dystonic limb pain in PD. DBS to the subthalamic nucleus may modulate central pain thresholds, and a pilot study of cranioelectric therapy warrants future research in the area.Conclusion: After optimizing dopaminergic therapy, understanding the type of pain a patient is experiencing is essential to optimizing pain control in PD. While recommendations can be made regarding the treatment options in each domain, evidence remains weak and future randomized controlled studies are needed.